- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT01292200
Breast Health in Chinese American Women
June 29, 2017 updated by: Judy Wang, Georgetown University
A RCT to Promote Mammography Adherence Among Chinese Immigrant Women
This four-and-a-half-year study will test the efficacy of viewing a theoretically based and culturally sensitive video followed by group discussion (vs.
single viewing) in increasing mammography use.
The results of this study will lead cancer control efforts to effectively decrease breast cancer screening disparities experienced by Chinese-America women.
Study Overview
Status
Completed
Conditions
Intervention / Treatment
Detailed Description
We will conduct a 4.5-year community-based RCT to study the impact of intervention approaches (small-group video discussion vs.
single video mode) on mammography used among Chinese immigrant women.
The small-group video discussion will be led by trained Chinese community health educators and trained bilingual research staff using a standardized structured protocol at all sites.
In the single video mode, we will mail the intervention materials to women to view and/or read at home.
We will recruit 974 Chinese women through our strong and well-established Chinese community partnerships in the metropolitan areas of Washington, DC (Lead PI: Dr. Judy Wang, Georgetown University-GU), New York (Site PI: Dr. Grace Ma at Temple University), and southern California (Site PI: Dr. Annette Maxwell, University of California, Los Angeles-UCLA).
Participants' eligibility are listed under "eligibility criteria".
We will not enroll US-born Chinese women as they are least likely to face cultural and language barriers to mammography and less likely to engage in our small-group discussion, which will be conducted in Chinese languages.
Also, we will not enroll short-term visitors as our study involves four interviews over a 2-year period.
Study Type
Interventional
Enrollment (Actual)
954
Phase
- Not Applicable
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Locations
-
-
California
-
Los Angeles, California, United States, 90095
- UCLA
-
-
District of Columbia
-
Washington, D.C., District of Columbia, United States, 20007
- Georgetown University
-
-
Pennsylvania
-
Philadelphia, Pennsylvania, United States, 19122
- Temple University
-
-
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
42 years and older (Adult, Older Adult)
Accepts Healthy Volunteers
No
Genders Eligible for Study
Female
Description
Inclusion Criteria:
- First generation Chinese women
- Aged 42 and older
- Have not had a mammogram in the past 2 years
- Have never had breast cancer
- Lived in the metropolitan DC, southern CA, and NY suburb; AND
- Have no mammography screening scheduled in the next 6 month from time of enrollment
Exclusion Criteria:
- Short-term visitors
- US-born Chinese Americans
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
- Primary Purpose: Screening
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
|---|---|
|
Experimental: watch DVD and small group discussion
Participants will watch the video in a group and discuss the video.
|
Women in the small-group discussion mode will be called by their community educators to determine possible dates, times, and places for group meetings.
The small group sessions will be conducted near the participants' homes.
Each small-group will consist of 5-10 participants who will first view a 20-minute video together and then discuss the content of the video as well as their barriers to screening for about 30 minutes.
A community educator and an RA at the study site will facilitate the discussion in Chinese languages according to a structured guide.
|
|
Placebo Comparator: watch video only
watch a 22 minutes long video at home by herself.
|
Women in the single video mode will receive a cultural video along with an information sheet on local free and low-cost screening programs by mail.
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
3rd interview about receipt of mammography screening
Time Frame: 6-month post-intervention
|
Measure the effect of small group video discussion on mammography screening adherence.
|
6-month post-intervention
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
4th interview about receipt of mammography screening
Time Frame: 21-month post-intervention
|
Measure the effect of small group video discussion on repeated mammography screening adherence.
|
21-month post-intervention
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Sponsor
Collaborators
Investigators
- Principal Investigator: Judy (Huei-Yu) Wang, Ph.D., Georgetown University
Publications and helpful links
The person responsible for entering information about the study voluntarily provides these publications. These may be about anything related to the study.
General Publications
- Wang JH, Mandelblatt JS, Liang W, Yi B, Ma IJ, Schwartz MD. Knowledge, cultural, and attitudinal barriers to mammography screening among nonadherent immigrant Chinese women: ever versus never screened status. Cancer. 2009 Oct 15;115(20):4828-38. doi: 10.1002/cncr.24517.
- Wang JH, Liang W, Schwartz MD, Lee MM, Kreling B, Mandelblatt JS. Development and evaluation of a culturally tailored educational video: changing breast cancer-related behaviors in Chinese women. Health Educ Behav. 2008 Dec;35(6):806-20. doi: 10.1177/1090198106296768. Epub 2007 Jun 29.
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start
July 1, 2010
Primary Completion (Actual)
December 21, 2016
Study Completion (Actual)
December 21, 2016
Study Registration Dates
First Submitted
February 7, 2011
First Submitted That Met QC Criteria
February 8, 2011
First Posted (Estimate)
February 9, 2011
Study Record Updates
Last Update Posted (Actual)
July 2, 2017
Last Update Submitted That Met QC Criteria
June 29, 2017
Last Verified
July 1, 2016
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
Other Study ID Numbers
- 2010-185
- R01CA142941-01A1 (U.S. NIH Grant/Contract)
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
UNDECIDED
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Breast Cancer
-
Baylor Breast Care CenterRecruitingBreast Cancer | Breast Neoplasm | Triple Negative Breast Cancer | Triple Negative Breast Neoplasms | HER2-positive Breast Cancer | Breast Cancer Stage II | Breast Cancer Female | Breast Cancer Stage III | Estrogen Receptor-positive Breast Cancer | Hormone Receptor-positive Breast Cancer | Breast Cancer InvasiveUnited States
-
Innocrin PharmaceuticalCompletedBreast Cancer | Advanced Breast Cancer | Metastatic Breast Cancer | Triple Negative Breast Cancer | Male Breast Cancer | ER+ Breast Cancer | Cancer of the BreastUnited States
-
Fred Hutchinson Cancer CenterNational Cancer Institute (NCI)CompletedInflammatory Breast Cancer | Male Breast Cancer | Stage IV Breast Cancer | Stage IIIB Breast Cancer | Estrogen Receptor-negative Breast Cancer | Estrogen Receptor-positive Breast Cancer | Progesterone Receptor-negative Breast Cancer | Progesterone Receptor-positive Breast CancerUnited States
-
Northwestern UniversityEisai Inc.UnknownMale Breast Cancer | Stage II Breast Cancer | Stage IIIA Breast Cancer | Stage IIIB Breast Cancer | Triple-negative Breast Cancer | Stage IA Breast Cancer | Stage IB Breast Cancer | Stage IIIC Breast Cancer | Estrogen Receptor-negative Breast Cancer | Progesterone Receptor-negative Breast Cancer | HER2-negative...United States
-
University of Colorado, DenverCompletedStage IV Breast Cancer | Stage II Breast Cancer | Stage IIIA Breast Cancer | Stage IIIB Breast Cancer | Stage IA Breast Cancer | Stage IB Breast Cancer | Stage IIIC Breast CancerUnited States
-
National Cancer Institute (NCI)TerminatedMale Breast Cancer | Stage IV Breast Cancer | Stage IIIA Breast Cancer | Stage IIIB Breast Cancer | Triple-negative Breast Cancer | Stage IIIC Breast Cancer | Recurrent Breast Cancer | Estrogen Receptor-negative Breast Cancer | Progesterone Receptor-negative Breast Cancer | HER2-negative Breast CancerCanada
-
Mayo ClinicMarker Therapeutics, Inc.CompletedHER2-positive Breast Cancer | Male Breast Cancer | Stage II Breast Cancer | Stage IIIA Breast Cancer | Stage IIIB Breast Cancer | Stage IIIC Breast CancerUnited States
-
Rutgers, The State University of New JerseyNational Cancer Institute (NCI); Rutgers Cancer Institute of New JerseyActive, not recruitingStage IIIA Breast Cancer | Stage IIIB Breast Cancer | Triple-negative Breast Cancer | Stage IIA Breast Cancer | Stage IIB Breast Cancer | Stage IIIC Breast Cancer | Estrogen Receptor-negative Breast Cancer | Progesterone Receptor-negative Breast Cancer | HER2-negative Breast CancerUnited States
-
University of Southern CaliforniaNational Cancer Institute (NCI)TerminatedMale Breast Cancer | Stage IV Breast Cancer | Stage II Breast Cancer | Stage IIIA Breast Cancer | Stage IIIB Breast Cancer | Stage IA Breast Cancer | Stage IB Breast Cancer | Stage IIIC Breast Cancer | Recurrent Breast CancerUnited States
-
University of Central FloridaFlorida Department of HealthRecruitingBreast Cancer | Breast Cancer Female | Breast Cancer Diagnosis | Breast Cancer Survivors | Breast Cancer Detection | Breast Cancer AwarenessUnited States
Clinical Trials on watch DVD and small group discussion
-
Universidad Nacional Andres BelloHospital de Simulación, Universidad Andres BelloCompleted
-
Nova Southeastern UniversityNational Institute on Drug Abuse (NIDA)CompletedHIV Infection | Substance AbuseUnited States
-
Eunice Kennedy Shriver National Institute of Child...National Institute on Deafness and Other Communication Disorders (NIDCD)TerminatedOvarian InsufficiencyUnited States
-
Joslin Diabetes CenterBeth Israel Deaconess Medical CenterTerminatedType 2 DiabetesUnited States
-
National Yang Ming Chiao Tung UniversityNot yet recruitingEnhancing Psychiatric Nursing Skills in Auditory Hallucination Assessment Via AR/VR and Virtual OSCERandomized Controlled TrialTaiwan
-
Riphah International UniversityRecruitingMuscle Strength | Physical Endurance | Functional PerformancePakistan
-
Cedars-Sinai Medical CenterWalter Reed National Military Medical CenterCompletedSarcoma | Neoplasms | Lymphoma | Lymphoma, Non-Hodgkin | Leukemia | Cancer | Breast Cancer | Head and Neck Cancer | Gynecologic Cancer | Glioblastoma | Multiple Myeloma | Colorectal Cancer | Hodgkin Lymphoma | Lung Cancer | Bone Cancer | Prostate Cancer | Brain Cancer | Skin Cancer | Pancreas Cancer | Gastrointestinal Cancer | Thyroid... and other conditionsUnited States
-
National Taiwan University HospitalNational Taiwan University; National Science and Technology CouncilNot yet recruitingAutism Spectrum Disorder | Sensory Processing Disorder
-
University of MichiganTranstimulation Research, IncWithdrawn
-
University of Illinois at ChicagoCompletedAlcohol Use DisorderUnited States